Particle.news
Download on the App Store
5 ARTICLES
·
2d ago

Savara Investors Pressed to Seek Lead Role in Securities Suit Before Nov. 7 Deadline

Investor notices follow an FDA refusal-to-file for the MOLBREEVI application that precipitated a one-day 31.7% share drop.

Overview

  • Multiple plaintiffs’ firms, including Rosen, Kirby McInerney, Levi & Korsinsky, Faruqi & Faruqi, and The Gross Law Firm, are urging Savara shareholders to move for lead-plaintiff status by November 7, 2025.
  • The pending class action covers purchases from March 2024 through May 23, 2025 and alleges Savara made false or misleading statements about MOLBREEVI and its BLA readiness.
  • Savara disclosed on May 27, 2025 that the FDA issued a Refusal to File because the MOLBREEVI BLA was not sufficiently complete and requested additional Chemistry, Manufacturing, and Controls data.
  • Following the disclosure, Savara’s stock fell about $0.90, or 31.69%, closing at $1.94 on May 27, 2025 after trading at $2.84 on May 23, 2025.
  • Notices state there is no cost to register, a lead plaintiff will direct the case, and class membership or recovery does not require serving as lead plaintiff; no class has been certified at this stage.